Impact of Healthcare Provider Awareness and Guidance on the Medical Cannabis Experience.

Q1 Medicine
Medical Cannabis and Cannabinoids Pub Date : 2025-02-18 eCollection Date: 2025-01-01 DOI:10.1159/000544125
Thomas A Clobes, Marshall M Mee, Jenna M Jimenez, Jesus Maldonado, Joshua R Song
{"title":"Impact of Healthcare Provider Awareness and Guidance on the Medical Cannabis Experience.","authors":"Thomas A Clobes, Marshall M Mee, Jenna M Jimenez, Jesus Maldonado, Joshua R Song","doi":"10.1159/000544125","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cannabis as a therapeutic agent is accessible to a growing number of people, though research suggests that many medical cannabis (MC) users undertake their cannabinoid therapy independently, without collaborating with a cannabis clinician or informing their primary care provider (PCP). The effects of medical collaboration or disclosure to PCP on outcomes of cannabinoid therapy are unknown. Researchers anticipate that those who collaborate with a cannabis clinician or disclose their medical cannabis use to their PCP will find MC to be more effective, use less delta-9-tetrahydrocannabinol (THC) and more cannabidiol (CBD), and experience fewer side effects.</p><p><strong>Methods: </strong>Through an online survey, medical cannabis users reported their cannabis usage patterns, health outcomes, PCP awareness, and collaboration with cannabis clinicians. These responses were analyzed using a variety of statistical tests to search for differences in reported efficacy, specific cannabinoid, and side effects between different levels of medical professional involvement (<i>n</i> = 988).</p><p><strong>Results: </strong>Patients who either worked with a cannabis clinician or reported their use of their PCP reported significantly higher efficacy (<i>p</i> < 0.001), and in the case of working specifically with a cannabis clinician, higher daily doses of cannabidiol were used (<i>p</i> < 0.001). CBD doses did not vary between those who had disclosed their MC use to their PCP and those who had not. There were no significant differences in THC doses or side effects identified between groups.</p><p><strong>Conclusion: </strong>The results indicated that undertaking cannabinoid therapy with PCP awareness or guidance from a cannabis clinician is associated with better outcomes.</p>","PeriodicalId":18415,"journal":{"name":"Medical Cannabis and Cannabinoids","volume":"8 1","pages":"47-57"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919312/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Cannabis and Cannabinoids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000544125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cannabis as a therapeutic agent is accessible to a growing number of people, though research suggests that many medical cannabis (MC) users undertake their cannabinoid therapy independently, without collaborating with a cannabis clinician or informing their primary care provider (PCP). The effects of medical collaboration or disclosure to PCP on outcomes of cannabinoid therapy are unknown. Researchers anticipate that those who collaborate with a cannabis clinician or disclose their medical cannabis use to their PCP will find MC to be more effective, use less delta-9-tetrahydrocannabinol (THC) and more cannabidiol (CBD), and experience fewer side effects.

Methods: Through an online survey, medical cannabis users reported their cannabis usage patterns, health outcomes, PCP awareness, and collaboration with cannabis clinicians. These responses were analyzed using a variety of statistical tests to search for differences in reported efficacy, specific cannabinoid, and side effects between different levels of medical professional involvement (n = 988).

Results: Patients who either worked with a cannabis clinician or reported their use of their PCP reported significantly higher efficacy (p < 0.001), and in the case of working specifically with a cannabis clinician, higher daily doses of cannabidiol were used (p < 0.001). CBD doses did not vary between those who had disclosed their MC use to their PCP and those who had not. There were no significant differences in THC doses or side effects identified between groups.

Conclusion: The results indicated that undertaking cannabinoid therapy with PCP awareness or guidance from a cannabis clinician is associated with better outcomes.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Medical Cannabis and Cannabinoids
Medical Cannabis and Cannabinoids Medicine-Complementary and Alternative Medicine
CiteScore
6.00
自引率
0.00%
发文量
18
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信